Moving forward from spleen response as an endpoint in randomized controlled trials in myelofibrosis.

Van Dijck R, Schnog JB, Te Boekhorst PAW.

Open source

DOI
10.3324/haematol.2025.288712
Published
2025-09-25
Container
Haematologica
Publisher
Not recorded
Open access
yes

Credibility signals

uncertain Score 53/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.3324/haematol.2025.288712,
  title = {Moving forward from spleen response as an endpoint in randomized controlled trials in myelofibrosis.},
  author = {Van Dijck R and  Schnog JB and  Te Boekhorst PAW.},
  year = {2026},
  journal = {Haematologica},
  doi = {10.3324/haematol.2025.288712},
  url = {https://doi.org/10.3324/haematol.2025.288712}
}

RIS

TY  - JOUR
TI  - Moving forward from spleen response as an endpoint in randomized controlled trials in myelofibrosis.
AU  - Van Dijck R
AU  -  Schnog JB
AU  -  Te Boekhorst PAW.
PY  - 2026
JO  - Haematologica
DO  - 10.3324/haematol.2025.288712
UR  - https://doi.org/10.3324/haematol.2025.288712
ER  - 

APA

R, V. D., JB, S., & PAW., T. B. (2026). Moving forward from spleen response as an endpoint in randomized controlled trials in myelofibrosis.. Haematologica. https://doi.org/10.3324/haematol.2025.288712

Source records